Funding

Hone Health Raises $228M in Funding Led by MarcyPen Capital Partners

Nov 19, 2026 | By Devin Jacobs

Hone Health Raises $228M in Funding Led by MarcyPen Capital Partners

SUMMARY

  • Hone Health raised $228 million in funding.
  • It will use the funds to expand its services.
  • Hone Health provides care focused on healthy ageing.

Hone Health, a New York-based physician-led longevity platform, has raised $228 million in funding. The financing includes $28 million in Series A extension equity and $200 million in growth financing from General Catalyst’s Customer Value Fund (CVF).

The equity round was led by MarcyPen Capital Partners, with participation from Pentland Ventures, Kinship Ventures, Hanwha, Gannet Capital, humbition, Comma Capital, ID Ventures and several strategic angel investors. The latest raise brings Hone Health’s total equity funding to $65 million.

The company plans to use the funding to expand its operations, and support further development. It will also publicly launch Hone Black, it's most comprehensive membership programme for personalised longevity care.

What is Hone Health?

Hone Health is a physician-led longevity platform that helps people manage their health and make informed decisions about ageing. It combines biomarker testing, one-on-one consultations with doctors and personalised treatment plans.

Read More:BrightAI Raises $97M in Funding Led by Smith Point Capital

It's services cover several areas, including testosterone replacement therapy, menopause hormone therapy, weight management, thyroid health, heart health, and sexual health. Treatment options also include prescription medications, supplements, peptides, and lifestyle guidance.

The company uses its proprietary AI clinical platform, Longevity OS, to give physicians a real time view of a patient's health across different medical specialties. This helps doctors build and adjust care plans based on individual health data, and changing goals.

About Hone Health

How Much Funding Has Hone Health Raised?

Hone Health has raised $228 million in its latest financing, including $28 million in equity and $200 million in growth financing from General Catalyst’s Customer Value Fund.

It's total equity funding has reached $65 million following the latest round.

Previously, the company raised a $33 million Series A in January 2025. That funding supported it's expansion beyond hormone health optimisation into broader longevity care.

Who Invested in Hone Health’s Series A Extension?

MarcyPen Capital Partners led the $28 million equity extension.

Other participating investors included Pentland Ventures, Kinship Ventures, Hanwha, Gannet Capital, humbition, Comma Capital and ID Ventures.

The round also included strategic angel investors such as David Grutman, Marcello Hernández, Nick Jonas, Joe Jonas, Kevin Jonas, Braxton Berrios, Kelly Rowland, Jason Strauss, Noah Tepperberg, Josh Childress, Quentin Dolan, Raj Gokal, Tushar Jain, Kyle Samani, Halle Tecco and Zachary Gordan.

Separately, General Catalysts Customer Value Fund provided $200 million in growth financing.

Why the Funding Matters

The funding will support Hone Health’s operational expansion, and development efforts. It also comes as the company prepares to introduce Hone Black, a concierge longevity programme that has been operating in stealth for the past year with a select group of patients.

Hone Black combines more than 1,600 health markers with ongoing medical care from a dedicated team of physicians. It's services include personalised treatment options, medical guidance and a broader approach to whole body health.

Hone Health funding

Who founded Hone Health?

Hone Health was founded by Saad Alam, Stuart Blitz, Alba Mertira and Matt Buckleman. The company is headquartered in New York City.

"Today, consumers have almost limitless options when it comes to preventative health, but what people are looking for is the highest level of insight into their metrics, so that they can make more informed decisions about their health," said Saad Alam, Co-Founder & CEO of Hone Health. "Hone combines comprehensive diagnostic testing, physician-led care, and AI-powered insights to deliver that level of understanding.

Market and Business Growth

Hone Health has treated more than 200,000 patients administered 750,000 tests, and processed 25 million health markers. These figures have helped the company build a large repository of hormone, and metabolic health data.

Since it's January 2025 Series A, Hone has expanded its services beyond hormone optimisation. It has introduced a cardiovascular programme that assesses health risks using advanced biomarkers alongside integrated whole body MRI scans from Prenuvo, and DEXA scans from BodySpec.

What Happens Next?

Hone Health plans to expand it's operations and continue developing it's platform, and services. Its next major step is the public launch of Hone Black, which will offer more extensive diagnostics and ongoing care from a dedicated physician team.

The company is also continuing to build its broader longevity offering across hormone health, cardiovascular care, weight management, and other medical areas.

Read More:Tesorai Raises $5.3M in Seed Funding, Reaches $8M Total

Recommended Stories for You